Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 3Completed 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Sarcoma 1

Conditions

Breast Neoplasms 6392Neoplasms 5365Prostatic Neoplasms 2966Carcinoma, Non-Small-Cell Lung 2709Colorectal Neoplasms 2679Lung Neoplasms 2267Multiple Myeloma 1663Lymphoma 1600Neoplasm Metastasis 1552Leukemia, Myeloid, Acute 1540Melanoma 1486Pancreatic Neoplasms 1470Ovarian Neoplasms 1423Leukemia 1389Head and Neck Neoplasms 1284Precursor Cell Lymphoblastic Leukemia-Lymphoma 1282Lymphoma, Non-Hodgkin 1231Colonic Neoplasms 1159Carcinoma, Hepatocellular 1142Stomach Neoplasms 1129Leukemia, Lymphocytic, Chronic, B-Cell 1090Brain Neoplasms 1050Rectal Neoplasms 980Lymphoma, Follicular 979Recurrence 976Uterine Cervical Neoplasms 926Glioblastoma 920Carcinoma, Renal Cell 882Lymphoma, Large B-Cell, Diffuse 853Hodgkin Disease 777

Interventions

Brentuximab Vedotin 2Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphomatoid Papulosis × Clear all
NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Seagen Inc.

Phase 2 Completed
40 enrolled
DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡